The SEVENFACT difference

SEVENFACT is the first inhibitor bypassing agent approved in the US in over 20 years1,2

A recombinant FVIIa, SEVENFACT differs molecularly from the other available bypassing agents

Difference in in vitro receptor binding affinity and glycosylation3

Difference in molecular weight3

Difference in clinical dosing3

A recombinant FVIIa, SEVENFACT differs molecularly from other available bypassing agents3

Phase 1b dose-ranging study investigated a range of doses to confirm in vitro dose-dependent thrombin generation4

Dose-dependency was seen in peak thrombin generation when measured from 5 minutes to 24 hours4

The highest thrombin generation was observed with the 225 μg/kg dose4

The impact of inhibitors

Living with an inhibitor is unpredictable

Controlling bleeds quickly is of critical concern

Delayed time to bleed resolution can lead to:

More blood in the joint and the hematoma5

Long-term joint damage6-8

Higher total costs6

More doses being required to stop the bleeding5

With no new inhibitor bypassing treatments approved in more than 20 years, SEVENFACT meets the ongoing need for new treatment options1,2

Find out how SEVENFACT is dosed to achieve your treatment goals1


Explore the manufacturing standards and purification process of SEVENFACT1


As seen in the clinical trial.


  1. SEVENFACT [Prescribing Information]. HEMA Biologics; 2020.
  2. NovoSeven [Prescribing Information]. Novo Nordisk; 2020.
  3. Biron-Andreani C, Schved J-F. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2019;12(1):21-28.
  4. Ducore J, Lawrence J, Simpson M, et al. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital hemophilia A or B patients, with or without inhibitors. Haemophilia. 2017;1-8
  5. Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009;15:752-759.
  6. Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16:487-494.
  7. Morfini M. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients. Eur J Haematol. 2015;96:111-118.
  8. Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014;12(suppl1):s319-s329.